Abstract: AIM: To investigate the efficacy and safety of donepezil combined olanzapine or single olanzapine in the treatment of behavioral and psychological symptoms. METHODS: 103 dementia patients with behavioral and psychological symptoms were randomly divided into donepezil combined olanzapine group and the single olanzapine group. The mini-mental state examination (MMSE) score were evaluated before treatment and the end of the study. The efficacies were evaluated in 2,4,6,8 weekend of the treatment by reduced rate of the behavioral pathology in Alzheimer's Disease Scale (BEHAVE-AD), ≥60% was markedly effective, ≥ 30% was effective, <30% was not effective. The treatment emergent symptom scale (TESS) assessment record treatment of the adverse drug reactions. RESULTS: The MMSE scores of donepezil combined olanzapine group increased more than two scores after the end than before treatment, it was statistically significant differences(t=2.060,P<0.05). The BEHAVE-AD scale scores of two groups before and after treatment compared to the fourth weekend were significantly decreased, there were statistically significant (P<0.01 or P<0.05). The effective rate was 88.46% and the markedly effective rate was 67.31% in donepezil combined olanzapine group.The effective rate was 70.59%, and the markedly effective rate was 45.10% in alone olanzapine group .There were statistically significant (χ²=5.067, P<0.05; χ²=5.701, P<0.05). There were no adverse drug reactions that can not tolerate. CONCLUSION: It is safe and effective that donepezil combined olanzapine treat behavioral and psychological symptoms of dementia patients, and better than single olanzapine.

Key words: Donepezil, Olanzapine, Behavioral and psychological symptoms of dementia